Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
Tillett W, Allen A, Tucker L, Chandler D, Ciurtin C, Davis C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Coates LC. Tillett W, et al. Rheumatology (Oxford). 2021 Apr 6;60(4):1588-1592. doi: 10.1093/rheumatology/keaa526. Rheumatology (Oxford). 2021. PMID: 33097948
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Rheumatology (Oxford). 2022 Aug 30;61(9):3514-3520. doi: 10.1093/rheumatology/keac260. Rheumatology (Oxford). 2022. PMID: 35640653 No abstract available.
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.
Tucker L, Allen A, Chandler D, Ciurtin C, Dick A, Foulkes A, Gullick N, Helliwell P, Jadon D, Jones G, Kyle S, Madhok V, McHugh N, Parkinson A, Raine T, Siebert S, Smith C, Tillett W, Coates LC. Tucker L, et al. Rheumatology (Oxford). 2022 Aug 30;61(9):e255-e266. doi: 10.1093/rheumatology/keac295. Rheumatology (Oxford). 2022. PMID: 35640657 No abstract available.
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.
Al-Janabi A, Martin P, Khan AR, Foulkes AC, Smith CH, Griffiths CEM, Morris AP, Eyre S, Warren RB; BSTOP Study Group and the BADBIR Study Group. Al-Janabi A, et al. Among authors: foulkes ac. J Allergy Clin Immunol. 2023 Nov;152(5):1237-1246. doi: 10.1016/j.jaci.2023.07.011. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536512 Free article.
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Al-Janabi A, et al. Among authors: foulkes ac. JAMA Dermatol. 2024 Jan 1;160(1):71-79. doi: 10.1001/jamadermatol.2023.4846. JAMA Dermatol. 2024. PMID: 38055239 Free PMC article.
27 results